Home › Research › Drug development
Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease
Novak E, Tochtrop M, Schlagel D, Fuller W.. South Dakota medicine : the journal of the South Dakota State Medical Association, 2024-02-01
Topic: Amyloid, tau and blood-test diagnosis
Various medicinal agents aimed at improving Alzheimer disease (AD) include cholinesterase inhibitors, memantine, aducanumab, and antioxidants. These medications are typically prescribed once AD is diagnosed in the clinical setting in order to slow progression. Though initiating treatment after being diagnosed with AD is important, significance should be placed on recognizing known acquired risk factors in order to potentially decrease the likelihood of developing dementia and perhaps specifically AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Novak, E., Tochtrop, M., Schlagel, D., & Fuller, W. (2024). Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease. South Dakota medicine : the journal of the South Dakota State Medical Association.
Vancouver
Novak E, Tochtrop M, Schlagel D, Fuller W. Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease. South Dakota medicine : the journal of the South Dakota State Medical Association. 2024. PMID: 38986163.
BibTeX
@article{novak2024-38986163,
author = {Novak, E. and Tochtrop, M. and Schlagel, D. and Fuller, W.},
title = {{Acquired Risk Factors that Influence Risk for Dementia and Possibly Alzheimer Disease}},
journal = {South Dakota medicine : the journal of the South Dakota State Medical Association},
year = {2024},
pmid = {38986163}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These medications are typically prescribed once AD is diagnosed in the clinical setting in order to slow progression.
- Though initiating treatment after being diagnosed with AD is important, significance should be placed on recognizing known acquired risk factors in order to potentially decrease the likelihood of developing dementia and perhaps specifically AD.
- This article summarizes the acquired factors that influence risk for dementia.
Why it matters
This article summarizes acquired factors that influence risk for dementia, noting that medications such as cholinesterase inhibitors, memantine, aducanumab and antioxidants are typically prescribed once Alzheimer's disease is diagnosed to slow progression. It argues that significance should be placed on recognizing known acquired risk factors to potentially decrease the likelihood of developing dementia and perhaps specifically Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 25 of the 92 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (South Dakota medicine : the journal of the South Dakota State Medical Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | University of South Dakota: institution h-index 270 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38986163) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 92 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related studies in Drug development
Also in Drug development
79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.